Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026

3.1 Small Molecule Cancer Drugs & its Comparison with Other Drugs Parameters
3.2 Small Molecule Cancer Drug vs. Immunotherapy
3.3 Small Molecule Cancer Drugs vs. Chemotherapy
3.4 Small Molecule Cancer Drug vs. Radiation Therapy
3.5 Small Molecule Cancer Drugs vs. Surgical Removal of Cancer Cells

4.1 Small Molecule Drugs & its Relation with Cancer Treatment
4.2 Mechanisms Targeted by Small Molecule Drugs in Cancer Therapy
4.2.1 Small Molecule Drugs as Growth Factor Kinase Inhibitor for Cancer Therapy
4.2.2 Small Molecule Drugs as DNA Damage Response Inhibitors for Cancer Therapy
4.3 Small Molecule Inhibitors & their Related Pathways

5.1 US
5.2 Europe
5.3 Asia
5.4 Rest of World

6.1 By Phase
6.2 By Formulation
6.3 By Company
6.4 By Country
6.5 By Indication
6.6 By Mechanism of Action

7.1 IACS-10759 Small Molecule Drug Discovery at MD Anderson
7.2 BET Small Molecule Inhibitor Discovery by Yale Researchers for the Cancer Patients
7.3 Amgen & Mirati’s Small Molecule Cancer Drug against KRAS Gene in Different Cancer Types
7.4 AOH1160 Small Molecule Research to Focus Breast Cancer at University of California

8.1 IACS & X-Chem to Undergo Small Molecule Cancer Therapies Development
8.2 MD Anderson, Artios Pharma & ShangPharma to Collaborate for Small Molecule ATR Inhibitor Program
8.3 Aptose Biosciences & Moffitt Cancer Center to Undergo Strategic Collaboration for the Development of New Multi-Targeting Epigenetic Therapeutic Agents
8.4 Merck & Taiho to Collaborate for Small KRAS- Targeting Cancer Drugs

9.1 Potential Insights about Factors Driving the Small Molecule Cancer Drug Market at Global Level
9.2 Challenges Concerning the Growth of Small Molecule Cancer Drug Market

12.1 Ribociclib (Kisqali)
12.2 Alpelisib (Piqray)
12.3 Abemaciclib (Verzenio)
12.4 Talazoparib (Telzenna)
12.5 Nertinib (Nerlynx)
12.6 Palbociclib (Ibrance)
12.7 Ixabepilone (Ixempra)
12.8 Anastrazole (Arimidex)
12.9 Lapatinib (Tykerb)
12.10 Toremifene (Fareston)
12.11 Letrozole (Femara)
12.12 Raloxifene (Evista)
12.13 Tamoxifen Oral Liquid (Soltamax)
12.14 Exemestane (Aromasin)
12.15 Testosterone Cypionate (Depo-Testosterone)
12.16 Fluoxymesterone (Halotestine/Androxy)
12.17 Fadrozole (Afema)
12.18 Tamibarotene (Amnolake)
12.19 Testosterone Propionate

13.1 Gilteritinib (Xospata)
13.2 Venetoclax (Venclexta)
13.3 Bosutinib (Bosulif)
13.4 Nilotinib (Tasigna)
13.5 Tretinoin (Vesanoid)
13.6 Clofarabine (Clolar)
13.7 Cytarabine/Daunorubicin (Vyxeos)
13.8 Dasatinib (Sprycel)
13.9 Ponatinib (Iclusig)
13.10 Enasidenib (Idhifa)
13.11 Ivosidenib (Tibsovo)
13.12 Cladribine (Mavenclad/Leustatin)
13.13 Mercaptopurine Oral Suspension (Purixan)
13.14 Methotrexate Oral Solution (Xatmep)
13.15 Pentostatin (Nipent)
13.16 Arsenic Trioxide (Trisenox)
13.17 Quizartinib (Vanflyta)
13.18 Histamine Dihydrochloride Injection (Ceplene)
13.19 Ubenimix (Bestatin)
13.20 Omacetaxine Mepesuccinate (Synribo)
13.21 Radotinib (Supect)

14.1 Gefitinib (Irresa)
14.2 Entrectinib (Rozlytrek)
14.3 Osimertinib (Tagrisso)
14.4 Erlotinib (Tarceva)
14.5 Brigatinib (Alunbirg)
14.6 Lorbrena (Lorlatinib)
14.7 Vinorelbine (Navelbine)
14.8 Zykadia (Certinib)
14.9 Pemetrexed (Alimta)
14.10 Alectinib (Alecensa)
14.11 Xalkori (Crizotinib)
14.12 Nintedanib (Ofev)
14.13 Anlotinib (Focus V)
14.14 Amrubicin (Calsed)
14.15 Icotinib (Conmana)

15.1 Copanlisib (Aliqopa)
15.2 Methoxsalen Solution (Uvadex)
15.3 Pralatrexate (Folotyn)
15.4 Bexarotene Topical (Targretin Gel)
15.5 Pixantrone (Pixuvri)
15.6 Belinostat (Beleodaq)
15.7 Zanubrutinib (Brukinsa)
15.8 Vorinostat (Zolinza)
15.9 Romidepsin (Istodax)
15.10 Bexarotene (Targretin)
15.11 Mechlorethamine (Valchlor/Ledaga)

16.1 Ixazomib (Ninlaro)
16.2 Melphalan Intravenous (Evomela/Chemostat)
16.3 Thalidomide (Thalomid)
16.4 Selinexor (Xpovio)
16.5 Panobinostat (Farydak)
16.6 Bortezomib (Velcade)
16.7 Pomalidomide (Pomalyst)
16.8 Dexamethasone High Dose (Neofordex)

17.1 Xtandi (Enzalutamide)
17.2 Apalutamide (Erleada)
17.3 Ertafitinib (Balversa)
17.4 Darolutamide (Nubeqa)
17.5 Bicalutamide (Casodex)
17.6 Nilutamide (Nilandron)
17.7 Abiraterone (Zytiga)
17.8 Xofigo (Radium Ra 223 dichloride)
17.9 Pedeliporfin (Tookad)

18.1 Avapritinib (Ayvakit)
18.2 Rivoceranib (Aitan)
18.3 Gimeracil/Oteracil/Tegafur (Teysuno/TS-1)
18.4 Eptaplatin/Heptaplatin

19.1 Fluciclovine 18F (Axumin)
19.2 Tc 99m Tilmanocept (Lymphoseek)
19.3 Perflubutane (Sonazoid)
19.4 Hexyl Aminolevulinate (Cysview)
19.5 Fluorocholine 18F (IASOcholine/Pcolina)
19.6 Gadobuterol (Gadavist)

20.1 Benimetinib (Mektovi)
20.2 Cobimetinib (Cotellic)
20.3 Sonidegib (Odomzo)
20.4 Vismodegib (Erivedge)
20.5 Imiquimod (Aldara/Zyclara)
20.6 Amivolevulinic Acid (Ameluz)
20.7 Methyl Aminolevulinate (Metvixia/Metvix PDT)
20.8 Vemurafenib (Zelboraf)

21.1 Irinotecan Liposome Injection (Onivyde)

22.1 Vendetanib (Caprelsa)

23.1 Axitinib (Inlyta)

24.1 Tipiracil/Trifluridine (Lonsurf)
24.2 Irinotecan (Camptosar)
24.3 Oxaliplatin (Eloxatin)
24.4 Raltitrexed (Tomudex)
24.5 Irinotecan-Eluting Beads (Paragon Beads/Debiri)
24.6 Fruquintinib (Elunate)

25.1 Larotectinib (Viktravi)

26.1 Fludarabin (Fludara/Oforta)
26.2 Gemcitabine (Gemzar)
26.3 Sorafnib (Nexavar)
26.4 Rucaparib (Rubraca)
26.5 Doxorubicin (Aridamycin)
26.6 Acalabrutinib (Calquence)
26.7 Ibrutinib (Imbruvica)
26.8 Azacitidine (Vidaza)
26.9 Lenalidomide (Revlimid)
26.10 Doxorubicin Liposomal (Doxil)
26.11 Tazemetostat (Tazverik)
26.12 Busulfan (Busulfex)
26.13 Afatinib (Gilotrif)
26.14 Gemcitabine (Infugem)
26.15 Carmustine Polifeprosan 20 wafer (Gliadel)
26.16 Eribulin (Halaven)
26.17 Paclitaxel-Protein Bound (Abraxane)
26.18 Trabectedine (Yondelis)
26.19 Paclitaxel (Taxol)
26.20 Docetaxel (Taxotere)
26.21 Idelalisib (Zydelig)
26.22 Duvelisib (Copiktra)
26.23 Regorafenib (Stivagra)
26.24 Nelarabine (Arranon)
26.25 Capecitabine (Xeloda)
26.26 Lenvatinib (Lenvima)
26.27 Olaparib (Lynparza)
26.28 Niraparib (Zejula)
26.29 Pazopanib (Votrient)
26.30 Alitretinoin Topical (Panretin)
26.31 Mitotane (Lysodren)
26.32 Valrubicin (Valstar)
26.33 Hydroxyurea (Hydrea)
26.34 Mitoxantrone (Novantrone)
26.35 Zoledronic Acid (Zometa/Reclast)
26.36 Fotemustine (Muforan)
26.37 Paclitaxel Nanoparticle (Nanoxel)
26.38 Topotecan (Hycamtin)
26.39 Decitabine (Decogen)
26.40 Tivozanib (Fotivda)
26.41 Telotristat Etiprate (Xermelo)
26.42 Imatinib (Gleevec)
26.43 Trametinib (Mekinist)
26.44 Cabozantinib (Cabometyx)
26.45 Encorafenib (Braftovi)
26.46 Dabrafenib (Tafinlar)
26.47 Sunintab (Sutent)
26.48 Levoleucovorin (Fusilev/Khapzory)
26.49 Bendamustine (Treanda/Belrapzo/Bendeka)
26.50 Forodesine (Fodosine/Mundesine)
26.51 Talaporfin (Laserphyrin)
26.52 Tucidinostat (Epidaza)
26.53 Doxorubicin Eluting Beads (DC Beads)
26.54 Temozolomide (Temodar)
26.55 Paclitaxel Polymeric Micelle Formulation (GenexolPM)
26.56 Docetaxel polymeric micelle (Nanoxel M)
26.57 Methotrexate
26.58 Treosulfan (Ovastat/Tercondi)
26.59 Belotecan (Camtobell)
26.60 Paclitaxel Liposomal(Lipusu/Bevetex)
26.61 Amsacrine (Amsa PD/Amekrin)
26.62 Cyclophosphamide
26.63 Docetaxel Nanosome (DoceAqualip)
26.64 Pamidronic acid (Aredia)
26.65 Mopidamol (Rapenton)
26.66 Nedaplatin (Aqupla)
26.67 Cytarabin/Cytarabin Liposomal (DepoCyt)
26.68 Dianhydrogalactitol (DAG for Injection)

27.1 Johnson & Johnson
27.2 Teva Pharmaceutical
27.3 Boehringer Ingelheim
27.4 Allergan
27.5 Pfizer
27.6 Bristol-Myers Squibb
27.7 Merck
27.8 GlaxoSmithKline
27.9 AstraZeneca
27.10 Gilead Sciences

Figure 1-1: Difference in the Size of Small Molecule Drug & Large Molecule Drug
Figure 1-2: Comparison between Small Molecule Drugs & Others
Figure 1-3: Brief Description for Small Molecule Drug Discovery
Figure 2-1: Small Molecule Drug Entry through Cell Membrane vs. Large Molecule Drug Entry
Figure 3-1: Important Parameters for Small Molecule Cancer Drugs
Figure 3-2: Small Molecule Cancer Drugs vs. Immunotherapy Treatment Procedure
Figure 3-3: Side Effects Caused by Small Molecule Cancer Drugs & Chemotherapeutic Agents
Figure 3-4: Small Molecule Cancer Drug Mechanism vs. Radiation Therapy
Figure 3-5: Small Molecule Cancer Drug Mechanism vs. Surgical Removal of Cancer Cells
Figure 4-1: Specific Targets for Small Molecule Cancer Drugs
Figure 4-2: Cancer Cell Growth in Absence & Presence of Small Molecule Cancer Drugs
Figure 4-3: Small Molecule Cancer Drugs Inhibiting DNA Damage Repair System Response
Figure 4-4: Specific Molecular Targets & their Indications for Small Molecule Cancer Drugs
Figure 4-5: Small Molecule Cancer Drugs & their Targets
Figure 5-1: Global - Small Molecule Cancer Drug Market (US$ Billion), 2019 - 2026
Figure 5-2: Global - Small Molecule Cancer Drug Market by Region (%), 2019
Figure 5-3: Global - Small Molecule Cancer Drug Market by Region (%), 2026
Figure 5-4: Global - Small Molecule Cancer Drug Market by Region (US$ Billion), 2019
Figure 5-5: Global - Small Molecule Cancer Drug Market by Region (US$ Billion), 2026
Figure 5-6: US – Parameters Responsible for Dominant Small Molecule Cancer Market
Figure 5-7: Europe – Factors Favoring Small Molecule Cancer Market
Figure 5-8: Comparison between different Parameters for Small Molecule Cancer Drug Market
Figure 6-1: Global Small Molecule Cancer Drug Clinical Pipeline by Phase, (Number of Drugs), 2020
Figure 6-2: Global Small Molecule Cancer Drug Clinical Pipeline by Phase, (%), 2020
Figure 6-3: Global Small Molecule Cancer Drug Clinical Pipeline by Formulation (Number), 2020
Figure 6-4: Global Small Molecule Cancer Drug Clinical Pipeline by Company (Number), 2020
Figure 6-5: Global Small Molecule Cancer Drug Clinical Pipeline by Country (Number), 2020
Figure 6-6: Global Small Molecule Cancer Drug Clinical Pipeline by Indication (Number), 2020
Figure 6-7: Global Small Molecule Cancer Drug Clinical Pipeline by Indication (Number), 2020
Figure 9-1: Arrival of Small Molecule Cancer Drugs into the Cancer Market
Figure 9-2: Driving Factors for Small Molecule Cancer Market
Figure 12-1: Kisqali – FDA Approval Year by Indication
Figure 12-2: Kisqali - Patent Issue & Expiration Year
Figure 12-3: Kisqali – Price for Supply of 21, 42 & 63 Tablets of 200mg (US$), May’2020
Figure 12-4: Kisqali – Duration of Treatment Cycle by Phase
Figure 12-5: kisqali – Annual Sales Value (US$ Million), 2017 - 2019
Figure 12-6: Global - kisqali Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 12-7: Piqray - Patent Issue & Expiration Year
Figure 12-8: Piqray – Price for Supply of 56 Tablets & Price per unit Tablet of 200-50mg & 150mg (US$), May’2020
Figure 12-9: Piqray – Price for Supply of 28 Tablets & Price per unit Tablet of 200mg (US$), May’2020
Figure 12-10: Piqray – Recommended & Reduced Dose (mg/day), May’2020
Figure 12-11: Piqray – Quarterly Sales Value (US$ Million), Q3-Q4’2019 & Q1’2020
Figure 12-12: Verzenio – Patent Issue & expiration Year
Figure 12-13: Verzenio – Price for a Supply of 14 Tablets & Price per unit Tablet (US$), May’2020
Figure 12-14: Verzenio – Dose by Type of Therapy (mg/Twice daily), May’2020
Figure 12-15: Verzenio Monotherapy – Initial & Reduced Dose (mg/Twice daily), May’2020
Figure 12-16: Verzenio Combinational – Initial & Reduced Dose (mg/Twice daily), May’2020
Figure 12-17: Verzenio – Annual Sales Value (US$ Million), 2017 - 2019
Figure 12-18: Global - Verzenio Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 12-19: Telzenna – FDA Approval & Patent Expiration Year
Figure 12-20: Talzenna – Price for Supply of 30 Tablets & Price per unit Tablet of Various Dose Regimens (US$), May’2020
Figure 12-21: Telzenna – Initial & reduced Dose (mg), May’2020
Figure 12-22: Nertininb – FDA Approval & Patent Expiration Year
Figure 12-23: Nerlynx – Price for 12 Tablet Supply & Price per unit Tablet of 20mg Tablet (US$), May’2020
Figure 12-24: Global – Nerlynx Sales Value (US$ Million), 2018 & 2019
Figure 12-25: Global – Nerlynx Quarterly Sales Value (US$ Million), 2019
Figure 12-26: Ibrance – FDA Approval by Indication
Figure 12-27: Ibrance – Patent Issue & Expiration Year
Figure 12-28: Ibrance – Price for 21 Capsule & Price per unit Capsule (US$), May’2020
Figure 12-29: Ibrance – Recommended & Reduced Dose (mg/day)
Figure 12-30: Ibrance – Annual Sales Value (US$ Million), 2017 - 2019
Figure 12-31: Ibrance - Annual Sales Value by Region (US$ Million), 2019
Figure 12-32: Ibrance – Annual Sales Value by Region (%), 2019
Figure 12-33: Ibrance – Quarterly Sales value (US$ Million), 2018 & 2019
Figure 12-34: Ixempra – FDA Approval & Patent Expiration Year
Figure 12-35: Ixempra – Price for 15m & 45mg Powder for Injection (US$), May’2020
Figure 12-36: Ixempra – Average & Maximum Cost of Single Treatment Cycle (US$), May’2020
Figure 12-37: Arimidex – FDA Approval & Patent Expiration Year
Figure 12-38: Arimidex – Price for 30 Tablets Supply & Price per unit Tablet (US$), May’2020
Figure 12-39: Anastrazole – Average Price for 30 Tablets Supply & Price per unit Tablet (US$), May’2020
Figure 12-40: Tykerb – Patent Issue & Expiration Year
Figure 12-41: Tykerb – Price for 150 Tablets & Price per Unit Tablet of 150mg (US$), May’2020
Figure 12-42: Tykerb – Recommended Dose by Indication (mg/day)
Figure 12-43: Fareston – FDA Approval & First Generic Approval Year
Figure 12-44: Fareston – Price for 30 Tablets & price per unit Tablet of 60mg (US$), May’2020
Figure 12-45: Generic Toremifene – Price for 30 Tablets & price per unit Tablet of 60mg (US$), May’2020
Figure 12-46: Fareston – FDA Approval & First Generic Approval Year
Figure 12-47: Femara – Price for 30 Tablets & price per unit Tablet of 2.5 mg (US$), May’2020
Figure 12-48: Generic Toremifene – Price for Various Tablet Supplies of 2.5mg (US$), May’2020
Figure 12-49: Raloxifdene – FDA Approval & First Generic Approval Year
Figure 12-50: Evista – Price for 30 Tablets Supply & Price per Unit tablet (US$), May’2020
Figure 12-51: Evista – Price for 100 Tablets Supply & Price per Unit tablet (US$), May’2020
Figure 12-52: Generic Raloxifene – Price for Various Supplies of 60mg Tablet (US$), May’2020
Figure 12-53: Soltamax – Price for 150 ml Supply & Price per unit ml of Oral Solution (US$), June’2020
Figure 12-54: Soltamax – Minimum & Maximum Dose for Metastatic Breast Cancer Treatment (mg/day)
Figure 12-55: Soltamax – Minimum & Maximum Duration for Breast Cancer Treatment (Years)
Figure 12-56: Aromasin – FDA Approval & First Generic Approval Year
Figure 12-57: Aromasin – Price for 30 Tablet Supply & Price per unit Tablet (US$), June’2020
Figure 12-58: Generic Exemestane – Price for 30 Tablet Supply & Price per unit Tablet (US$), June’2020
Figure 12-59: Depo-testosterone – Price for 10ml & Price per ml of 100mg/ml Intramuscular Solution (US$), June’2020
Figure 12-60: Depo-testosterone – Price for 10ml & 1 ml Supplies of 200mg/ml Intramuscular Solution (US$), June’2020
Figure 12-61: Fluoxymesterone – FDA Approval Year by Brand Name
Figure 12-62: Androxy – Price for Supply of 100 Tablets & Price per unit Tablet (US$), June’2020
Figure 12-63: Fluoxymesterone – Minimum & Maximum Recommended Dose (mg), June’2020
Figure 12-64: Fluoxymesterone – Minimum & Maximum Cost of Daily Treatment (US$), June’2020
Figure 12-65: Afema– Price for Supply of 10mg & 50mg Powder (US$), June’2020
Figure 12-66: Amnolake – PMDA Approval & Patent Expiration Year
Figure 13-1: Xospata – Patent Issue Expiration Year
Figure 13-2: Xospata – Price for 30 Tablets & Price per unit Tablet (US$), May’2020
Figure 13-3: Xospata – Daily, Monthly & Annual Treatment Cost (US$), May’2020
Figure 13-4: Global - Xospata Quarterly Sales Value (JPY/US$ Million), 2018 & 2019
Figure 13-5: Venetoclax - Patent Issue & Expiration year
Figure 13-6: Venetoclax – Price for Various Supplies of 10mg Tablet (US$), May’2020
Figure 13-7: Venetoclax – Price for Various Supplies of 50mg Tablet (US$), May’2020
Figure 13-8: Venetoclax – Price for Various Supplies of 50mg Tablet (US$), May’2020
Figure 13-9: Venetoclax – Price for 42 Kit & Price per unit Kit (US$), May’2020
Figure 13-10: Venetoclax Monotherapy – Recommended Dose by Treatment Week for CLL Management (mg/day), May’2020
Figure 13-11: Venetoclax Combinational – Recommended Dose in Initial & Subsequent Treatment Cycle for CLL (mg/Cycle), May’2020
Figure 13-12: Venetoclax Monotherapy – Recommended Dose for AML (mg/day), May’2020
Figure 13-13: Venclexta – Annual Sales Value (US$ Million), 2017 - 2019
Figure 13-14: Venclexta - Annual Sales Value by Region (US$ Million), 2019
Figure 13-15: Venclexta – Annual Sales Value by Region (%), 2019
Figure 13-16: Global - Venclexta Quarterly Sales Value (US$ Million), 2019
Figure 13-17: Bosulif – Patent Issue & Expiration Year
Figure 13-18: Bosulif – Price for 120 Tablet & Price per Unit of 100mg Tablet (US$), May’2020
Figure 13-19: Bosulif – Price for 30 Tablet & Price per Unit of 400 & 500mg Tablet (US$), May’2020
Figure 13-20: Bosulif – Recommended Dose for Newly Diagnosed & Therapy Resisted CML (mg)
Figure 13-21: Tasigna – FDA Approval Year by Indication
Figure 13-22: Tasigna – Patent Issue & Expiration Year
Figure 13-23: Tasigna – Price for 120 Capsules & Price per unit Capsule of 50mg (US$), May’2020
Figure 13-24: Tasigna – Price for 28 & 112 Capsules & Price per unit Capsule of 100 & 200 mg (US$), May’2020
Figure 13-25: Tasigna – Recommended Dose by Indication (mg Twice Daily), May’2020
Figure 13-26: Tasigna – Recommended Pediatric Dose by Surface Area (mg Twice Daily), May’2020
Figure 13-27: Vesanoid – FDA Approval & First Generic Approval Year
Figure 13-28: Tretinoin – price for 30 Capsule Supply 7 Price per Unit Capsule (US$), May’2020
Figure 13-29: Tretinoin – price for 100 Capsule Supply & Price per Unit Capsule (US$), May’2020
Figure 13-30: Tretinoin – Minimum & Maximum Treatment Cost (US$), May’2020
Figure 13-31: Clolar – FDA Approval & First Generic Approval Year
Figure 13-32: Clolar – Price for 20ml Supply & Price per ml of Intravenous Solution (US$), May’2020
Figure 13-33: Generic Clofarabine – Price for 20ml Supply & Price per ml of Intravenous Solution (US$), May’2020
Figure 13-34: Clolar – Recommended dose & Dose after Reduction (mg/m2/day)
Figure 13-35: Vyxeos – FDA Approval & Patent Expiration Year
Figure 13-36: Vyxeos – Price for 1, 2 & 5 Powder for Injection (US$), May’2020
Figure 13-37: Vyxeos – Number of Drug Administration Required in Different Treatment Cycles (Dose/Cycle), May’2020
Figure 13-38: Sprycel – FDA Approval Year by Tablet Strength
Figure 13-39: Sprycel – Patent Issue & Expiration Year
Figure 13-40: Sprycel – Price for 60 Tablets & Price per Unit Tablet of 20mg, 50mg and 70mg (US$), May’2020
Figure 13-41: Sprycel – Price for 30 Tablets & Price per Unit Tablet of 80mg, 100mg and 140mg (US$), May’2020
Figure 13-42: Sprycel – Recommended Dose by Indication (mg/day)
Figure 13-43: Sprycel – Recommended Pediatric Dose by Weight (mg/day)
Figure 13-44: Iclusig – FDA Approval Year by Tablet Strength (US$), May’2020
Figure 13-45: Iclusig - Patent Issue & Expiration Year
Figure 13-46: Iclusig – Price for 30 tablets & Price per unit Tablet of 15mg & 45mg (US$), May’2020
Figure 13-47: Iclusig – Recommended Initial & Reduced Dose (mg/day)
Figure 13-48: Iclusig – Global Sales Value (US$ Million), 2018 & 2019
Figure 13-49: Global - Iclusig Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 13-50: Idhifa – Patent Issue & Expiration Year
Figure 13-51: Idhifa – Price for 30 Tablets & Price per unit of Oral Tablet (US$), May’2020
Figure 13-52: Idhifa – Daily & Full Treatment Cost (US$), May’2020
Figure 13-53: Idhifa – Annual Sales Value (US$ Million), 2017 & 2018
Figure 13-54: Idhifa – US v/s Rest of World Annual Sales Value (US$ Million), 2019
Figure 13-55: Idhifa – US v/s Rest of World Annual Sales Value (%), 2019
Figure 13-56: Idhifa – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 13-57: Tibsovo – FDA Approval Year by Indication
Figure 13-58: Tibsovo – Patent Issue & Expiration Year
Figure 13-59: Tibsovo – Price for 60 Tablets & Price per unit of 250mg Tablet (US$), May’2020
Figure 13-60: Tibsovo – Cost of Daily Treatment & Full Treatment Cost (US$), May’2020
Figure 13-61: Global – Tibsovo Sales Value (US$ Million), 2018 & 2019
Figure 13-62: Global – Tibsovo Quarterly Sales Value (US$ Million), 2019
Figure 13-63: Cladribine – FDA Approval Year by Brand Name
Figure 13-64: Mavenclad – Merck’s Patent Issue & Expiration Year
Figure 13-65: Mavenclad – Ares Trading’s Patent Issue & Expiration Year
Figure 13-66: Mavenclad – Price for various Tablet Supplies of 10mg (US$), June’2020
Figure 13-67: Generic Cladribine – Price for 10 & 1ml Intravenous Solution (US$), June’2020
Figure 13-68: Cladribine – Recommended Dose by Route of Administration (mg/Kg/day)
Figure 13-69: Purixan – FDA Approval & Exclusivity Expiration Year
Figure 13-70: Purixan – Price for 100ml Supply & Price per ml of Oral Suspension (US$), June’2020
Figure 13-71: Purixan – Minimum & Maximum Recommended Dose (mg/Kg)
Figure 13-72: Xatmep – Patent Issue & Expiration Year
Figure 13-73: Xatmep – Price for 60ml Supply & Price per ml of Oral Solution (US$), June’2020
Figure 13-74: Xatmep – Price for 100ml Supply & Price per ml of Oral Solution (US$), June’2020
Figure 13-75: Xatmep – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), June’2020
Figure 13-76: Nipent – FDA Approval & First Generic Approval Year
Figure 13-77: Pentostatin – Price for Single Vial of Generic & Branded Pentostatin (US$), May’2020
Figure 13-78: Trisenox – FDA Approval Year by Strength
Figure 13-79: Trisenox – FDA Approval & First Generic Approval Year
Figure 13-80: Arsenic Trioxide – Price for 100ml Supply & Price per ml of Branded & Generic Intravenous Solution of 1mg/ml Dose, May’2020
Figure 13-81: Arsenic Trioxide – Price for 60ml Supply & Price per ml of Branded & Generic Intravenous Solution of 2mg/ml Dose (US$), May’2020
Figure 13-82: Arsenic Trioxide – Duration of Induction & Consolidation Treatment Cycle (Days)
Figure 13-83: Arsenic Trioxide – Number of Required Induction & Consolidation Treatment Cycle
Figure 13-84: Vanflyta– Recommended Dose for AML Treatment (mg/day)
Figure 13-85: Vanflyta– Recommended Dose & Dose after Reduction (mg/day)
Figure 13-86: Ceplene – Europe Market Authorisation & Orphan Designation Year
Figure 13-87: Ceplene – Cost of Single Administration, Single Day Treatment & One Treatment Cycle (US$/GBP), June’2020
Figure 13-88: Synribo – Patent Issue & Expiration Year
Figure 13-89: Synribo – Treatment Phase in Induction & Maintenance Cycle (Weeks/Cycle)
Figure 13-90: Supect – Daily, Monthly & Annual Treatment Cost (US$), June’2020
Figure 14-1: Iserra – FDA Approval Year by Indication
Figure 14-2: Iserra – Patent & Exclusivity Expiration Year
Figure 14-3: Iserra – Price for 30 Tablets & Price per unit Tablet (US$), May’2020
Figure 14-4: Iserra – Annual Sales Value (US$ Million), 2017 - 2019
Figure 14-5: Iserra - Annual Sales Value by Region (US$ Million), 2019
Figure 14-6: Iserra – Annual Sales Value by Region (%), 2019
Figure 14-7: Global - Iserra Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 14-8: Rozlytrek - FDA Approval & Patent Expiration Year
Figure 14-9: Rozyltrek - Price for 30 Capsules Supply & Price per unit of 100 mg Oral Tablet (US$), April’2020
Figure 14-10: Rozyltrek - Price for 90 Capsules Supply & Price per unit of 200 mg Oral Tablet (US$), April’2020
Figure 14-11: Rozyltrek – Pediatric Dose by Surface Area (mg), April’2020
Figure 14-12: Tagrisso - Patent Issue & Expiration Year
Figure 14-13: Tagrisso - Price for 30 Tablet Supply & Price per unit of 200 mg Oral Tablet (US$), April’2020
Figure 14-14: Tagrisso - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 14-15: Tagrisso – Annual Sales Value (US$ Million), 2017 - 2019
Figure 14-16: Tagrisso - Annual Sales Value by Region (US$ Million), 2019
Figure 14-17: Tagrisso – Annual Sales Value by Region (%), 2019
Figure 14-18: Global - Tagrisso Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 14-19: Tarceva – FDA Approval & First Generic Approval Year
Figure 14-20: Tarceva – Price for Supply of 30 Tablets & Price per unit Tablet of Various Dose Regimens (US$), May’2020
Figure 14-21: Generic Erlotinib – Average Price for Supply of 30 Tablets & Price for 20 Tablets of various Doses (US$), May’2020
Figure 14-22: Tarceva – Recommended dose by Indication (mg/day)
Figure 14-23: Alunbirg – Patent Issue & Expiration Year
Figure 14-24: Alunbirg – Price for 30 Tablets of Various Dose Regimens (US$), June’2020
Figure 14-25: Alunbirg – Recommended & Reduced Dose (mg)
Figure 14-26: Lorbrena – FDA Approval & Patent expiration Years
Figure 14-27: Lorbrena - Price for 30 Tablet Supply & Price per unit of 25mg Oral Tablet (US$), April’2020
Figure 14-28: Lorbrena - Price for 30 Tablet Supply & Price per unit of 100 mg Oral Tablet (US$), April’2020
Figure 14-29: Lorbrena - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 14-30: Navelbine – FDA Approval & First Generic Approval Year
Figure 14-31: Navelbine – Price for 1ml & 5ml Supply of Intravenous Solution (US$), May’2020
Figure 14-32: Generic Venorelbine – Price for 1ml & 5ml Supply of Intravenous Solution (US$), May’2020
Figure 14-33: Zykadia – FDA Approval by Indication
Figure 14-34: Zykadia - Patent Expiration Year by Assignee
Figure 14-35: Zykadia - Price for 84 Capsules Supply & Price per unit of Oral Capsule (US$), April’2020
Figure 14-36: Zykadia - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 14-37: Alimta – FDA Approval Year by Dose Regimen
Figure 14-38: Alimta – Patent Issue & Expiration Year
Figure 14-39: Alimta – Price for 100mg & 500mg Intravenous Powder (US$), April’2020
Figure 14-40: Alimta – Treatment Cycle required in Combination with Pembrolizumab v/s Cisplatin, April’2020
Figure 14-41: Alimta – Cost of Single Treatment Cycle & Full Treatment Cost of NSCLC (US$), April’2020
Figure 14-42: Alimta – Annual Sales Value (US$ Billion), 2016 - 2019
Figure 14-43: Alimta – US v/s Rest of World Annual Sales Value (US$ Million), 2019
Figure 14-44: Alimta – US v/s Rest of World Annual Sales Value (%), 2019
Figure 14-45: Alimta – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 14-46: Alimta – US Quarterly Sales Value (US$ Million), 2019
Figure 14-47: Alecensa – FDA Approval by Indication
Figure 14-48: Alecensa - Patent Issue & expiration Year
Figure 14-49: Alecensa – Price for 240 Tablet Supply & Price per unit of Oral Tablet (US$), April’2020
Figure 14-50: Alecensa - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 14-51: Xalkori - Patent Issue & Expiration Year
Figure 14-52: Xalkori - Price for 60 Capsule Supply & Price per unit of Oral Capsule (US$), April’2020
Figure 14-53: Xalkori – Recommended & Reduced Daily Dose (mg)
Figure 14-54: Ofev – Patent Issue & Expiration Year
Figure 14-55: Ofev – Price for 60 Capsule & Price per unit Capsule (US$), June’2020
Figure 14-56: Ofev – Recommended & Reduced Dose (mg/Twice Daily)
Figure 14-57: Global - Ofev Sales Value (EUR/US$), 2017 - 2019
Figure 14-58: Focus V – Recommended & Reduced Dose (Mcg)
Figure 14-59: Focus V – Duration of Treatment Phase & Rest Phase in One Cycle (Days)
Figure 14-60: Conmana – Price for 21 Tablets & Price Per unit Tablet (CNY/US$), June’2020
Figure 15-1: Aliqopa – Patent Issue & Expiration Year
Figure 15-2: Aliqopa – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), May’2020
Figure 15-3: Uvadex – Price for 120 ml Supply & Price per unit ml of Intravenous Solution (US$), June’2020
Figure 15-4: Uvadex – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 15-5: Folotyn – Patent Issue & Expiration Year
Figure 15-6: Folotyn – Price for Supply of 1ml & 2ml Intravenous Solution of 20mg/ml Dose (US$), June’2020
Figure 15-7: Folotyn – Recommended Initial & Reduced Dose (mg/m2)
Figure 15-8: Bexarotene Topical – FDA Approval & Patent Expiration Year
Figure 15-9: Targretin Gel – Price for 60gm gel & Price per gram of 1% Gel (US$), May’2020
Figure 15-10: Pixantrone – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 15-11: Pixuvri – Cost of Single Administration, One Treatment Cycle & Full Treatment (US$/GBP), June’2020
Figure 15-12: Beledaq – Patent Issue & Expiration Year
Figure 15-13: Beledaq – Cost of Single Administration & cost of Single Treatment Cycle (US$), May’2020
Figure 15-14: Brukinsa – Patent Issue & Expiration Year
Figure 15-15: Brukinsa – Price for Supply of 120 tablets & Price Per unit Tablet (US$), May’2020
Figure 15-16: Brukinsa – Recommended Dose & Dose after Reduction (mg/day)
Figure 15-17: Zolinza – FDA Approval & Patent Expiration Year
Figure 15-18: Zolinza – Price for Supply of 120 tablets & Price Per unit Tablet (US$), May’2020
Figure 15-19: Zolinza – Recommended Dose & Dose after Reduction (mg/day)
Figure 15-20: Romidepsin – FDA Approval Year by Indication
Figure 15-21: Romidepsin – Price for a Supply of 10mg branded & generic Intravenous Powder (US$), May’2020
Figure 15-22: Istodax – Cost of Single Dose & Single Treatment cycle (US$), May’2020
Figure 15-23: Tragretin – FDA Approval & First Generic Approval Year
Figure 15-24: Targetrin – Price for 100 Capsule Supply & Price per unit Capsules (US$), May’2020
Figure 15-25: Generic bexarotene – Price for Capsule Supply & Price per unit Capsules (US$), May’2020
Figure 15-26: Bexarotene – Daily Treatment Cost using Branded v/s Generic (US$), May’2020
Figure 15-27: Valchlor – Number of Patents by Assignee
Figure 15-28: Valchlor – Patent Expiration Year by Asignee
Figure 15-29: Valchlor – Price for 60gm Gel & Price per Gram of 0.016% Gel (US$), May’2020
Figure 16-1: Ninlaro – Number of Patents by Assignee Name
Figure 16-2: Ninlaro – Patent Expiration by Assignee Name
Figure 16-3: Ninlaro – Price for 30 Capsules & price per unit Capsules of Various Dose Regimen (US$), May’2020
Figure 16-4: Ninlaro – Recommended Dose & Reduced Dose (mg/week for 3weeks/Cycle)
Figure 16-5: Evomela – Patent Issue & Expiration Year
Figure 16-6: Evomela – Duration of Single Treatment Cycle & Full Palliative Treatment (Weeks)
Figure 16-7: Evomela – Cost of Single Treatment Cycle & Full Palliative Treatment (US$) June’2020
Figure 16-8: Thalomid – FDA Approval Year by Capsule Strength
Figure 16-9: Thalomid – Patent Issue & Expiration Year
Figure 16-10: Thalomid – Price for 10 & 280 Capsules of 50mg Dose (US$), June’2020
Figure 16-11: Thalomid – Price for 140 Capsules & Price per unit Capsules of 100mg Dose (US$), June’2020
Figure 16-12: Thalomid – Price for 112 Capsules & Price per unit Capsules of 150mg Dose (US$), June’2020
Figure 16-13: Thalomid – Price for 84 Capsules & Price per unit Capsules of 200mg Dose (US$), June’2020
Figure 16-14: Xpovio – FDA Approval & Patent Expiration Year
Figure 16-15: Xpovio – Price for 12 Tablet Supply & Price per unit Tablet of 20mg Tablet (US$), May’2020
Figure 16-16: Xpovio – Quarterly Sales Value (US$ Million), May’2020
Figure 16-17: Farydak – Patent Issue & Expiration Year
Figure 16-18: Farydak – Price for 30 Tablet Supply & Price per unit Tablet (US$), May’2020
Figure 16-19: Farydak – Number of Treatment Cycle required by Type of Therapy, May’2020
Figure 16-20: Velcade – FDA Approval Year by Indication
Figure 16-21: Velcade – Patent Issue & Expiration Year
Figure 16-22: Bortezomib – Generic Approval By Companies
Figure 16-23: Global – Velcade Sales Value (US$ Million), 2017 & 2018
Figure 16-24: Pomalyst – FDA Approval & Patent Expiration Year
Figure 16-25: Pomalyst – Price for 21 Capsules Supply & Price per unit Capsule of Various Dose Regimens (US$), May’2020
Figure 16-26: Pomalyst – Price for 100 Capsules Supply & Price per unit Capsule of Various Dose Regimens (US$), May’2020
Figure 16-27: Pomalyst – Recommended Initial & Reduced Dose (mg/day)
Figure 16-28: Global - Pomalyst Sales Value (US$ Million), 2017 - 2019
Figure 16-29: Pomalyst – US v/s Rest of World Annual Sales Value (US$ Million), 2018
Figure 16-30: Pomalyst – US v/s Rest of World Annual Sales Value (%), 2018
Figure 16-31: Pomalyst – Quarterly Sales Value (US$ Million), 2019
Figure 16-32: Neofordex – Price for 10 Tablets & Price per unit Tablet (GBP/US$), June’2020
Figure 17-1: Xtandi – FDA Approval Year by Indication
Figure 17-2: Xtandi – Patent Issue & Expiration Year
Figure 17-3: Xtandi – Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), May’2020
Figure 17-4: Xtandi – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April’2020
Figure 17-5: Xtandi – Cost of Single Capsule & Daily Treatment Cost (US$), April’2020
Figure 17-6: Erleada – Aragon related Patent Issue & expiration Year
Figure 17-7: Erleada – University of California related Patent Issue & expiration Year
Figure 17-8: Erleada – Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), April’2020
Figure 17-9: Erleada – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April’2020
Figure 17-10: Balversa - Patent Issue & Expiration year
Figure 17-11: Balversa – Price for 56 & 84 Tablet Supplies of 3mg (US$), May’2020
Figure 17-12: Balversa – Price for 28 & 56 Tablet Supplies of 4mg (US$), May’2020
Figure 17-13: Balversa – Price for 28 Tablets & Price Per unit Tablet (US$), May’2020
Figure 17-14: Balversa – Initial & Increased Dose for Prostate Cancer (mg/day), May’2020
Figure 17-15: Balversa – Recommended Dose after Reduction for Prostate Cancer (mg/day), May’2020
Figure 17-16: Nubeqa – Aragon Related Patent Issue & Expiration Year
Figure 17-17: Nubeqa – Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), April’2020
Figure 17-18: Nubeqa – Price of Single Tablet & Daily Treatment Cost (US$), April’2020
Figure 17-19: Casodex – FDA Approval & Patent Expiration Year
Figure 17-20: Casodax – Price for 30 Tablets Supply & Price per unit Tablet (US$), May’2020
Figure 17-21: Generic Bicalutamide – Price for 30 Tablets Supply & Price per unit Tablet (US$), May’2020
Figure 17-22: Nilandrone – FDA Approval & First Generic Approval Year
Figure 17-23: Eloxatin – FDA Approval Year by Strength of Tablet
Figure 17-24: Nilandrone – Price for 30 Tablet Supply & Price per unit tablet of 150mg (US$), May’2020
Figure 17-25: Nilandrone – Recommended Dose for Prostate Cancer Treatment (mg/day), May’2020
Figure 17-26: Zytiga – FDA Approval by Indication
Figure 17-27: Zytiga – FDA approval & First generic Approval Year
Figure 17-28: Zytiga – Price for Supply of 120 tablets & Price Per unit Tablet of 250mg (US$), May’2020
Figure 17-29: Zytiga – Price for Supply of 60 tablets & Price Per unit Tablet of 500mg (US$), May’2020
Figure 17-30: Generic Abiraterone – Price for Supply of 30 Tablets & 120 tablets & Price Per unit Tablet of 250mg (US$), May’2020
Figure 17-31: Abiraterone – Daily Treatment Cost Branded v/s Generic (US$), May’2020
Figure 17-32: Xofigo – Patent Issue & expiration Year
Figure 17-33: Xofigo – Duration of One Treatment Cycle & Full Treatment Duration for Prostate Cancer (Weeks), April’2020
Figure 17-34: Tookad – Price for 183mg Supply & Cost of Treatment (GBP/US$), June’2020
Figure 18-1: Ayvatik - Patent Issue & Expiration Year
Figure 18-2: Verzenio – Price for a Supply of 30 Tablets & Price per unit Tablet (US$), May’2020
Figure 18-3: Ayvakit – Initial & Reduced Dose (mg), May’2020
Figure 18-4: Focus V – Recommended Initial & Reduced Dose (mg/day)
Figure 18-5: Teysuno – Approval Year in Europe & Japan
Figure 18-6: Teysuno – Price for 84 Capsules & Price per unit Capsule (INR/US$), June’2020
Figure 18-7: TS1– Price for 56 Capsules & Price per unit Capsule (US$), June’2020
Figure 18-8: Teysuno – Recommended & Reduced Dose (mg/m2 Twice Daily)
Figure 18-9: Eptaplatin – Min8imum & MaximumRecommended Dose (mg/m2), June’2020
Figure 19-1: Axumin – Number of Patents by Assignee
Figure 19-2: Axumin – Patent Expiration Year by Assignee
Figure 19-3: Lymphoseek – FDA Approval Year by Indication
Figure 19-4: Lymphoseek – Patent Issue & Expiration Year
Figure 19-5: Sonazoid – PMDA Approval Year by Indication
Figure 19-6: Cysview – Patent Issue & Expiration Year
Figure 19-7: Gadavist – FDA Approval Year by Supply
Figure 19-8: Gadavist – Patent Issue & Expiration Year
Figure 19-9: Gadavist – Price for Various Supplies of Intravenous Solution (US$), June’2020
Figure 20-1: Mektovi – Number of Patents by Asignee
Figure 20-2: Mektovi – Patent Expiration Year by Assignee
Figure 20-3: Mektovi – Price for 180 Tablet Supply & Price per unit Tablet (US$), May’2020
Figure 20-4: Mektovi – Recommended & Reduced Dose (mg/twice daily), May’2020
Figure 20-5: Cotellic – Number of Patents by Assignee
Figure 20-6: Cotellic – Patent Expiration Year by Asignee
Figure 20-7: Cotellic – Price for 63 Tablets Supply & Price per unit Tablet (US$), May’2020
Figure 20-8: Cotellic – Recommended & Reduced Dose (mg/day)
Figure 20-9: Odomzo – Novartis Patent Issue & Expiration Year
Figure 20-10: Odomzo – IRM’s Patent Issue & Expiration Year
Figure 20-11: Odomzo – Price for 30 Capsules & price per unit Capsules of 200mg (US$), May’2020
Figure 20-12: Erivedge – Patent Issue & Expiration Year
Figure 20-13: Erivedge – Price for 28 Capsules & Price per unit of 150mg Capsule (US$), May’2020
Figure 20-14: Imiquimod – FDA Approval Year by Brand Name
Figure 20-15: Aldara – Patent Issue & Expiration Year
Figure 20-16: Aldara – Price for 12 Cream Supply & Price per unit 5% Cream (US$), June’2020
Figure 20-17: Zyclara – Price for 7.5gm Supply & Price per unit of 2.5% Cream (US$), June’2020
Figure 20-18: Zyclara – Price for 7.5gm Supply & Price per unit of 3.75% Cream (US$), June’2020
Figure 20-19: Zyclara – Price for 28gm Supply & Price per unit of 3.75% Cream (US$), June’2020
Figure 20-20: Generic Imiquimod – Price for 7.5gm Supply & Price per unit of 3.75% Cream (US$), June’2020
Figure 20-21: Generic Imiquimod – Price for Supply of 12 & 24 Creams of 5% Concentration (US$), June’2020
Figure 20-22: Imiquimod – Treatment Duration by Indication (Weeks)
Figure 20-23: Ameluz – FDA Approval & Patent Expiration Year
Figure 20-24: Ameluz – Price for 2gm Supply & Price per unit of 10% Cream (US$), May’2020
Figure 20-25: Gliolan – Price for 10 Vials & Price per unit Vial of 1.5gm Powder for Injection (US$), May’2020
Figure 20-26: Methyl Aminolevulinate – FDA Approval Year by Indication
Figure 20-27: Metvix PDT – Minimum & Maximum Cost of Treatment (US$/CND), June’2020
Figure 20-28: Zelboraf – Plexxikon’s Patent Issue & Expiration Year
Figure 20-29: Zelboraf – Roche’s Patent Issue & Expiration Year
Figure 20-30: Zelboraf – Price for 112 Tablets & Price per unit Tablet (US$), May’2020
Figure 21-1: Onivyde – FDA Approval & Patent Expiration Year
Figure 21-2: Onivyde – Cost of 10 ml Supply & Price per ml of Intravenous Dispersion (US$), May’2020
Figure 21-3: Onivyde – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), May’2020
Figure 21-4: Global - Onivyde Annual Sales Value (US$/EUR Million), 2017 - 2019
Figure 21-5: Global - Onivyde Quarterly Sales Value (US$/EUR Million), 2019
Figure 21-6: Global - Onivyde Quarterly Sales Value (US$/EUR Million), 2018
Figure 22-1: Caprelsa – Patent Issue & Expiration Year
Figure 22-2: Caprelsa – Price for 30 Tablets & Price per unit of 100mg Tablet (US$), May’2020
Figure 22-3: Caprelsa – Price for 30 Tablets & Price per unit of 300mg Tablet (US$), May’2020
Figure 22-4: Caprelsa – Recommended Initial & Reduced Dose (mg/daily)
Figure 23-1: Inflyta - FDA Approval by Type of Therapy
Figure 23-2: Inflyta – Patent Issue & Expiration Year
Figure 23-3: Inlyta – Price for 180 Capsule Supply & Price per unit Capsules of 1mg (US$), May’2020
Figure 23-4: Inlyta – Price for 60 Capsule Supply & Price per unit Capsules of 5mg (US$), May’2020
Figure 24-1: Lonsurf – FDA Approval & Patent Expiration Year
Figure 24-2: Lonsurf - Price for various Supplies of 6.14mg-15mg Tablet (US$), April’2020
Figure 24-3: Lonsurf - Price for Various Supplies of 8.19mg-20mg Tablet (US$), April’2020
Figure 24-4: Lonsurf - Recommended Dose by Surface Area (mg per day)
Figure 24-5: Camptosar – FDA Approval & First Generic Approval Year
Figure 24-6: Camptosar – FDA Approval Year by Strength of Intravenous Solution
Figure 24-7: Camptosar – Price for Various Supplies of 20mg/ml Intravenous Solution (US$), May’2020
Figure 24-8: Generic Irinotecan – Average Price for Various Supplies of 60mg Tablet (US$), May’2020
Figure 24-9: Camptosar Monotherapy – Treatment Phase & Rest Phase in 125mg/ m2 Dose (Week), May’2020
Figure 24-10: Eloxatin – FDA Approval & First Generic Approval Year
Figure 24-11: Eloxatin – FDA Approval Year by Strength of Intravenous Solution
Figure 24-12: Eloxatin – Price for 10ml & 20ml Intravenous Solution (US$), May’2020
Figure 24-13: Generic Oxaliplatin – Price for various supplies of Intravenous Solution (US$), May’2020
Figure 24-14: Eloxatin – Duration of Single Treatment Cycle & Full Treatment (Weeks), May’2020
Figure 24-15: Eloxatin – Recommended & Reduced Dose (mg/m2 weeks), May’2020
Figure 24-16: Raltitrexed – Recommended Initial & Reduced Dose (mg/m2/2 weeks)
Figure 24-17: Raltitrexed – Cost of Single Treatment Cycle & Full Treatment
Figure 24-18: Fruquintinib – Duration of Treatment Phase & Rest Phase in Single Treatment Cycle (Days)
Figure 25-1: Viktravi – Number of Patents by Assignee Name
Figure 25-2: Viktravi – Patents Expiration Year by Assignee Name
Figure 25-3: Vitraki – Price for 60 Capsules Supply of 25mg & 100mg Dose (US$), May’2020
Figure 25-4: Vitraki – Price for 100 ml Supply & Price per ml of Oral Solution (US$), May’2020
Figure 25-5: Vitraki – Recommended & Reduced Adult Dose (mg Twice Daily), May’2020
Figure 25-6: Vitraki – Recommended & Reduced Pediatric Dose (mg/m2 Twice Daily), May’2020
Figure 26-1: Fludarabin – FDA Approval Year by Brand Name
Figure 26-2: Fludarabin – Price for 50mg Intravenous Powder & 2 ml Intravenous Solution for Injection (US$), May’2020
Figure 26-3: Gemzar – FDA Approval & First Generic Approval Year
Figure 26-4: Gemzar – Price for the Supply of 1 Gram & 200mg Powder for Injection (US$), May’2020
Figure 26-5: Gemzar – Cost of Single Treatment Cycle & Cost of Single Administration (US$), May’2020
Figure 26-6: Nexavar – FDA Approval Year by Indication
Figure 26-7: Nexavar – Price for a supply of 120 Tablets & Price per unit Tablet (US$), May’2020
Figure 26-8: Nexavar – Daily, Monthly & Annual Treatment Cost (US$), May’2020
Figure 26-9: Nexavar – Global Sales Value (US$ Million), 2018 & 2019
Figure 26-10: Global - Nexavar Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 26-11: Rubraca – FDA Approval Year by Indication
Figure 26-12: Rubraca – FDA Approval Year by Strength
Figure 26-13: Rubraca - Number of Patents by Assignee
Figure 26-14: Rubraca - Patents Expiration Year by Assignee
Figure 26-15: Rubraca – Price for a Supply of 60 Tablets & Price per unit Tablet (US$), May’2020
Figure 26-16: Rubraca – Recommended Initial & Reduced Dose (mg/twice daily)
Figure 26-17: Rubraca – Global Sales Value (US$ Million), 2018 & 2019
Figure 26-18: Global - Rubraca Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 26-19: Aridamycin – Price for 10mg & 50mg Powder for Injection (US$), May’2020
Figure 26-20: Aridamycin – Price for Various Supplies of Solution for Injection (US$), May’2020
Figure 26-21: Generic Doxorubicin – Price for Various Supplies of Solution for Injection (US$), May’2020
Figure 26-22: Aridamycin Monotherapy – Minimum & Maximum Dose (mg/m2 once every 3 Weeks)
Figure 26-23: Aridamycin Combinational – Minimum & Maximum Dose (mg/m2 once every 3 Weeks)
Figure 26-24: Calquence – FDA Approval Year by Indication
Figure 26-25: Calquence – Number of Patents by Assignee
Figure 26-26: Calquence – Patent Expiration Year by Assignee
Figure 26-27: Calquence - Price for 60 capsules & Price Per unit Capsule (US$), May’2020
Figure 26-28: Calquence – Recommended dose by Type of Therapy (mg/day), May’2020
Figure 26-29: Calquence – Annual Sales Value (US$ Million), 2017 - 2019
Figure 26-30: Calquence - Annual Sales Value by Region (US$ Million), 2019
Figure 26-31: Calquence – Annual Sales Value by Region (%), 2019
Figure 26-32: Global - Calquence Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 26-33: Ibrutinib – FDA Approval Year by Indication
Figure 26-34: Ibrutinib – FDA Approval Year by Dosage Form
Figure 26-35: Imbruvica – Price for 90 & 120 Capsule Supplies of 140mg (US$), May’2020
Figure 26-36: Imbruvica Capsule – Price for 28 Capsule & Price Per unit Capsule of 70mg (US$), May’2020
Figure 26-37: Imbruvica Tablet – Price for 28 Tablets & Price Per unit Tablet of Various Doses (US$), May’2020
Figure 26-38: Imbruvica – Recommended Daily Dose by Indication (mg), May’2020
Figure 26-39: Imbruvica – Annual Sales Value (US$ Billion), 2017 - 2019
Figure 26-40: Imbruvica - Annual Sales Value by Region (US$ Million), 2019
Figure 26-41: Imbruvica – Annual Sales Value by Region (%), 2019
Figure 26-42: Global - Imbruvica Quarterly Sales Value (US$ Million), 2019
Figure 26-43: Vidaza – FDA & First generic Approval Year
Figure 26-44: Vidaza – Branded v/s Generic Price for 100mg Intravenous powder (US$), May’2020
Figure 26-45: Vidaza – Dose for Initial & Subsequent Treatment Cycle (mg/m2)
Figure 26-46: Vidaza – Cost of Initial & Subsequent Treatment Cycle (US$), May’2020
Figure 26-47: Revlimid – FDA Approval Year by Indication
Figure 26-48: Revlimid – FDA Approval & Patent Expiration Year
Figure 26-49: Revlimid – Price for 28 capsules & 100 Capsules of 2.5mg, 5mg & 10mg Capsules (US$), May’2020
Figure 26-50: Revlimid – Price for 21 capsules & 100 Capsules of 15mg, 20mg & 25mg Capsules (US$), May’2020
Figure 26-51: Revlimid – Recommended Daily Dose by Indications (mg)
Figure 26-52: Global – Revlimid Sales Value (US$ Million), 2017 - 2019
Figure 26-53: Global – Revlimid Quarterly Sales Value (US$ Million), 2019
Figure 26-54: Doxil – FDA Approval & First Generic Approval Year
Figure 26-55: Doxil – Price for Supply of 10 ml & Price per ml of Intravenous Solution (US$), April’2020
Figure 26-56: Doxil – Price for Supply of 25 ml & Price per ml of Intravenous Solution (US$), April’2020
Figure 26-57: Lipodox – Price for Supply of 10 ml & Price per ml of Intravenous Solution (US$), April’2020
Figure 26-58: Lipodox 50 – Price for Supply of 25 ml & Price per ml of Intravenous Solution (US$), April’2020
Figure 26-59: Doxil – Recommended Single Dose by Indication (mg/m2), April’2020
Figure 26-60: Doxil – Duration of Single Treatment Cycle (Week), April’2020
Figure 26-61: Doxil – Cost of Single Treatment Cycle & Annual Treatment Cost of Ovarian Cancer (US$), April’2020
Figure 26-62: Doxil – Cost of Single Treatment Cycle & Annual Treatment Cost of Kaposi’s sarcoma (US$), April’2020
Figure 26-63: Tazverik – FDA Approval & Patent Expiration Year
Figure 26-64: Tazverik – Price for 240 Tablets & price per unit Tablet (US$), May’2020
Figure 26-65: Tazverik – Recommended Dose & Dose after Reduction (mg Twice Daily), May’2020
Figure 26-66: Busulfan – FDA Approval & First Generic Approval Year
Figure 26-67: Busulfex – Price for 80ml Supply & Price per ml of Intravenous Solution (US$), May’2020
Figure 26-68: Busulfex – Cost of Single Administration, Single Day & Full Treatment Cost (US$), May’2020
Figure 26-69: Gilotrif – FDA Approval Year by Indication
Figure 26-70: Gilotrif - Patent Issue & Expiration Year
Figure 26-71: Gilotrif – Price for 30 Tablet Supply & Price per unit of Oral Tablet (US$), June’2020
Figure 26-72: Gilotrif - Recommended & Reduced Dose for NSCLC Treatment (mg per day), June’2020
Figure 26-73: Infugem – Patent Issue & Expiration Year
Figure 26-74: Infugem – Price for Supply of 120ml & Price per ml of 10ml/ml Intravenous Solution (US$), June’2020
Figure 26-75: Infugem – Price for Supply of 240ml & Price per ml of 10ml/ml Intravenous Solution (US$), June’2020
Figure 26-76: Gliadel – FDA Approval & Patent Expiration Year
Figure 26-77: Gliadel – Price for 8 Implanted Devices & Price per unit Tablet (US$), May’2020
Figure 26-78: Halaven – FDA Approval Year by Indication
Figure 26-79: Halaven – Patent Issue & Expiration Year
Figure 26-80: Halaven – Price for 2ml Supply & Price per ml of Intravenous Solution (US$), May’2020
Figure 26-81: Halaven – Recommended & Reduced Dose (mg/m2twice daily), May’2020
Figure 26-82: Abraxane – FDA Approval Year by Indication
Figure 26-83: Abraxane – US & Europe Patent Expiration Year
Figure 26-84: Abraxane – Recommended Single Dose by Indication (mg/m2), April’2020
Figure 26-85: Abraxane – Duration of Single Treatment Cycle (Week), April’2020
Figure 26-86: Abraxane – Cost of Single Treatment Cycle & Annual Treatment Cost of Breast Cancer (US$), April’2020
Figure 26-87: Abraxane – Cost of Single Treatment Cycle & Annual Treatment Cost of NSCLC (US$), April’2020
Figure 26-88: Abraxane – Cost of Single Treatment Cycle & Annual Treatment Cost of Pancreatic Cancer (US$), April’2020
Figure 26-89: Abraxane – Annual Sales Value (US$ Million), 2017 - 2019
Figure 26-90: Abraxane – US v/s Rest of World Annual Sales Value (US$ Million), 2019
Figure 26-91: Abraxane – US v/s Rest of World Annual Sales Value (US$ Million), 2019
Figure 26-92: Abraxane – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 26-93: Abraxane – US Quarterly Sales Value (US$ Million), 2019
Figure 26-94: Yondelis – Patent Issue & Expiration Year
Figure 26-95: Yondelis - Recommended & Reduced Dose (mg/m2/3weeks)
Figure 26-96: Global - Yondelis Annual Sales Value (US$/EUR Million), 2017 - 2019
Figure 26-97: Global - Yondelis Quarterly Sales Value (US$/EUR Million), 2019
Figure 26-98: Taxol - FDA Approval & First Generic Approval Year
Figure 26-99: Paclitaxel – Average Price for Various Supplies of 6mg/ml Intravenous Solution (US$), May’2020
Figure 26-100: Paclitaxel – Recommended Dose by Cancer Type (mg/m2/3weeks)
Figure 26-101: Taxotere – FDA Approval year by Strength
Figure 26-102: Taxotere – First Generic Approval year by Strength
Figure 26-103: Docetaxel – FDA Approval year by Companies
Figure 26-104: Taxotere – Price for 4ml Supply & Price per ml of 20mg/ml Intravenous Solution (US$, May’2020
Figure 26-105: Docetaxel – Average Price for 2ml, 8ml & 16ml Supply 10mg/ml Intravenous Solution (US$, May’2020
Figure 26-106: Docetaxel – Average Price for 1ml, 4ml, 8ml & 10ml Supply 20mg/ml Intravenous Solution (US$, May’2020
Figure 26-107: Docetaxel – Minimum & Maximum Dose for breast Cancer Management (mg/m2/3 weeks)
Figure 26-108: Zydelig – Number of Patents by Asignee
Figure 26-109: Zydelig – Patent Expiration Year by Asignee
Figure 26-110: Zydelig – Price for 60 Tablet Supply & Price per Unit Tablet (US$), May’2020
Figure 26-111: Zydelig – Recommended & Reduced Dose (mg/day)
Figure 26-112: Global - Zydelig Sales Value (US$ Million), 2017 - 2019
Figure 26-113: Zydelig – Annual Sales Value by Region (US$ Million), 2019
Figure 26-114: Zydelig – Annual Sales Value by Region (%), 2019
Figure 26-115: Zydelig – Quarterly Sales Value (US$ Million), 2018 - 2019
Figure 26-116: Copiktra – Interllikine’s Patent Issue & Expiration Year
Figure 26-117: Copiktra – Infinity Pharma’s Patent Issue & Expiration Year
Figure 26-118: Copiktra – Price for 56 Capsules Supply & Price per unit Capsule (US$), May’2020
Figure 26-119: Copiktra – Recommended & Reduced Dose (mg/day)
Figure 26-120: Stivarga – FDA Approval Year by Indication
Figure 26-121: Stivarga – Patent Issue & Expiration Year
Figure 26-122: Stivarga – Price for 84 Tablets Supply & Price per unit Tablet (US$), May’2020
Figure 26-123: Stivarga – Recommended & Reduced Dose (mg/day)
Figure 26-124: Arranon – FDA Approval Year & Patent Expiration Year
Figure 26-125: Arranon – Price for 50ml & 300ml intravenous Solution of 5mg/ml Dose (US$), May’2020
Figure 26-126: Arranon – Adult & Pediatric Dose (mg/m2)
Figure 26-127: Xeloda – FDA Approval Year & First Generic Approval Year
Figure 26-128: Capecitabine – Price for 60 Tablet Supply & Price per unit of 150mg Branded & Generic tablet (US$), May’2020
Figure 26-129: Xeloda – Price for 120 Tablet Supply & Price per unit of 500mg tablet (US$), May’2020
Figure 26-130: Capecitabine – Price for 120 Tablet Supply & Price per unit of 500mg tablet (US$), May’2020
Figure 26-131: Capecitabine – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 26-132: Lenvima – FDA Approval Year by Indication
Figure 26-133: Lenvima – Patent & Exclusivity Expiration Year
Figure 26-134: Lenvima – Price for 30 Capsules & Price per unit Capsules of 4mg & 10mg (US$), May’2020
Figure 26-135: Lenvima – Price for 60 Capsules & Price per unit Capsules 8mg, 14mg & 20mg (US$), May’2020
Figure 26-136: Lenvima – Price for 90 Capsules & Price per unit Capsules (US$), May’2020
Figure 26-137: Lenvima – Dose by Cancer Type (mg/day), May’2020
Figure 26-138: Lenvima – Dose for Hepatocellular Carcinoma by Weight (mg/day), May’2020
Figure 26-139: Lenvima – Annual Sales Value (US$ Million), 2018 & 2019
Figure 26-140: Global - Lenvima Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 26-141: Lynparza – FDA Approval Year by Indication
Figure 26-142: Lynparza - Number of Patent Issued by Assignee Name
Figure 26-143: Lynparza – Patent Expiration Year by Assignee
Figure 26-144: Lynparza – Price for 60 & 120 Tablet Supply & Price per Unit Tablet (US$), May’2020
Figure 26-145: Lynparza – Recommended Dose & Dose after Reduction (mg/day)
Figure 26-146: Lynparza – Annual Sales Value (US$ Million), 2017 - 2019
Figure 26-147: Lynparza - Annual Sales Value by Region (US$ Million), 2019
Figure 26-148: Lynparza – Annual Sales Value by Region (%), 2019
Figure 26-149: Global - Lynparza Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 26-150: Tasigna – Patent Issue & Expiration Year
Figure 26-151: Zejula – Price for 30 capsules Supply & Price per unit of Oral capsule (US$), April’2020
Figure 26-152: Zejula – Price for 90 capsules Supply & Price per unit of Oral capsule (US$), April’2020
Figure 26-153: Zejula – Recommended Dose & Dose after Reduction (mg/day), April’2020
Figure 26-154: Zejula – Annual Sales Value (US$/GBP Million), 2017 - 2019
Figure 26-155: Zejula – Annual Sales Value by Region (US$/GBP Million), 2019
Figure 26-156: Zejula – Annual Sales Value by Region (%), 2019
Figure 26-157: Global - Zejula Quarterly Sales Value (US$ Million), 2019
Figure 26-158: Votrient – FDA Approval Year by indication
Figure 26-159: Votrient – Patent Issue & Expiration Year
Figure 26-160: Votrient – Price for 120 Tablets Supply & Price per unit Tablet (US$), May’2020
Figure 26-161: Global - Votrient Sales Value (US$ Million), 2017 - 2019
Figure 26-162: Votrient – US v/s Rest of World Annual Sales Value (US$ Million), 2019
Figure 26-163: Votrient – US v/s Rest of World Annual Sales Value (%), 2019
Figure 26-164: Votrient – Quarterly Sales Value (US$ Million), 2019
Figure 26-165: Panretin – FDA Approval & patent Expiration Year
Figure 26-166: Panretin – Price for 60gm Supply & Price per unit of Gel (US$), May’2020
Figure 26-167: Panretin – Minimum & Maximum Duration of Treatment (Weeks)
Figure 26-168: Lysodren – Price for 100 Tablets Supply & Price per unit of Tabalet (US$), May’2020
Figure 26-169: Lysodren – Minimum & Maximum Daily Dose (mg)
Figure 26-170: Valstar – FDA Approval & First Generic Approval Year
Figure 26-171: Valstar – Price for a Supply of 20ml & Price per ml of Intravesical Solution (US$), May’2020
Figure 26-172: Valstar – Cost of Single Treatment Cycle & Full Treatment (US$), May’2020
Figure 26-173: Hydroxyurea – FDA Approval & First Generic Approval Year
Figure 26-174: Hydrea – Price for a Supply of 100 Capsules & Price per unit Capsule (US$), May’2020
Figure 26-175: Generic Hydroxyurea – Price for a Supply of 100 Capsules & Price per unit Capsule (US$), May’2020
Figure 26-176: Generic Hydroxyurea – Dose Incrimination after Every 12 Weeks (mg/day)
Figure 26-177: Mitoxantron – FDA Approval & First Generic Approval Year
Figure 26-178: Mitoxantron – Price for 10ml, 12.5ml & 15 ml Supply of 2mg/ml Intravenous Solution (US$), June 2020
Figure 26-179: Mitoxantron – Minimum & Maximum Dose for Prostate Cancer (mg/3weeks)
Figure 26-180: Zometa – FDA Approval & First Generic Approval Year
Figure 26-181: Reclast – FDA Approval & First Generic Approval Year
Figure 26-182: Zometa – Price for 5ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 26-183: Reclast – Price for 10ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 26-184: Generic Zoledronic Acid – Price for 5ml and 200ml Supply of 4mg/ml Intravenous Solution (US$), June’2020
Figure 26-185: Generic Zoledronic Acid – Price for 100ml & Price per ml of 4mg/100ml Intravenous Solution (US$), June’2020
Figure 26-186: Generic Zoledronic Acid – Price for 100ml & Price per ml of 5mg/100ml Intravenous Solution (US$), June’2020
Figure 26-187: Fotemustine – Price for 4ml & Price per ml of Intravenous Vial (US$), May’2020
Figure 26-188: Fotemustine – Minimum & Maximum Duration of Rest Phase (Weeks)
Figure 26-189: Fotemustine - Duration of Induction & Maintenance Cycle (Weeks)
Figure 26-190: Nanoxel – DCGI Approval Year by Indication
Figure 26-191: Nanoxel – Price for 15ml Supply & Price per ml of Intravenous Solution (INR/US$), June’2020
Figure 26-192: Nanoxel – Price for 5ml Supply & Price per ml of Intravenous Solution (INR/US$), June’2020
Figure 26-193: Nanoxel – Minimum & Maximum Dose (mg/3weeks)
Figure 26-194: Hycamtin Injectable Solution – FDA Approval & First Generic Approval Year
Figure 26-195: Topotecan Capsule – FDA Approval & First Generic Approval Year
Figure 26-196: Generic Hycamtin – Price for supply of 4gm intravenous Powder & 4ml Intravenous Solution (US$), May’2020
Figure 26-197: Hycamtin – Cost of Single Treatment Cycle by Indication (US$), May’2020
Figure 26-198: Decogen – FDA Approval & first Generic Approval Year
Figure 26-199: Decitabine – Price for 50mg Branded & Generic Intravenous Powder (US$), May’2020
Figure 26-200: Decitabine – Cost of Single Dose, Single day & Single Treatment Cycle using 15mg/m2/Thrice a Day Dose regimen (US$), May’2020
Figure 26-201: Decitabine – Cost of Single Day & Single Treatment Cycle using 20mg/m2/Daily Dose regimen (US$), May’2020
Figure 26-202: Fotivda – Price for 21 Capsules & Price per unit Capsule (US$), June’2020
Figure 26-203: Fotivda – Recommended & Reduced Dose (Mcg)
Figure 26-204: Xermelo – Patent Issue & Expiration Year
Figure 26-205: Xermelo – Price for 56 Capsules & Price per unit Capsule (US$), June’2020
Figure 26-206: US - Xermelo sales Value (US$ Million), 2018 & 2019
Figure 26-207: US – Xermelo Quarterly Sales Value (US$ Million), 2019
Figure 26-208: Gleevec – FDA Approval by Dosage Form
Figure 26-209: Gleevec – FDA Approval by Indication
Figure 26-210: Gleevec – Patent Issue & Expiration Year
Figure 26-211: Imatinib – Price for 30 Tablet supply of Branded & Generic Imatinib 400mg (US$), May’2020
Figure 26-212: Imatinib – Price for 90 Tablet supply of Branded & Generic Imatinib 400mg (US$), May’2020
Figure 26-213: Gleevec – Recommended Dose by Indication (mg/Day)
Figure 26-214: Mekinist – FDA Approval by Indication
Figure 26-215: Mekinist – Number of Patents by Assignee
Figure 26-216: Mekinist – Patent Expiration Year by Assignee
Figure 26-217: Mekinist – Price for 30 Tablets & Price per Unit Tablet of 0.5mg (US$), May’2020
Figure 26-218: Mekinist – Price for 30 Tablets & Price per unit Tablet of 2mg (US$), May’2020
Figure 26-219: Mekinist – Recommended Initial Dose & dose After Reduction (mg/day), May’2020
Figure 26-220: Cabometyx – FDA Approval by Indication
Figure 26-221: Cabometyx – Patent Issue & Expiration Year
Figure 26-222: Cabometyx – Price for 30 Tablet Supply & Price per unit Tablet (US$), May’2020
Figure 26-223: Cabometyx – Recommended Initial Dose & Dose After Reduction (mg/day), May’2020
Figure 26-224: Cabometyx – Annual Sales Value (US$ Million), 2018 & 2019
Figure 26-225: Cabometyx – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 26-226: Braftovi – FDA Approval by Indication
Figure 26-227: Braftovi – Number of Patents by Assignee
Figure 26-228: Braftovi – Patent Expiration Year by Assignee
Figure 26-229: Braftovi – Price for 180 Tablets & Price per unit Tablet (US$), May’2020
Figure 26-230: Braftovi – Recommended dose by Indication
Figure 26-231: Braftovi – Daily Treatment Cost by Indication (US$), May’2020
Figure 26-232: Tafinlar – FDA Approval by Indication
Figure 26-233: Tafinlar – Number of Patents by Assignee
Figure 26-234: Tafinlar – Patent Expiration Year by Assignee
Figure 26-235: Talfinlar – Price for 120 Tablets & Price per unit of 50mg Tablet (US$), May’2020
Figure 26-236: Talfinlar – Price for 120 Tablets & Price per unit of 75mg Tablet (US$), May’2020
Figure 26-237: Talfinlar – Recommended Dose & Dose after reduction (mg/day), May’2020
Figure 26-238: Sutent – FDA Approval by Indication
Figure 26-239: Sutent – Patent Issue & Expiration Year
Figure 26-240: Sutent – Patent Issue & Expiration Year
Figure 26-241: Sutent – Recommended Dose by Indication (mg/day)
Figure 26-242: Levoleucovorin – FDA Approval Year by Brand Name
Figure 26-243: Fusilev – Patent Issue & Expiration Year
Figure 26-244: Levoleucovorin – Price for Intravenous Powder by Brand name & Dose (US$), June’2020
Figure 26-245: Bendamustine – FDA Approval Year by Brand Name
Figure 26-246: Treanda – Patent Issue & Expiration Year
Figure 26-247: Bendeka – Number of Patent by Assignee
Figure 26-248: Bendeka – Patent Expiration Year by Assignee
Figure 26-249: Bendamustine – FDA & First Generic Approval Year
Figure 26-250: Bendamustine – Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 26-251: Bendeka – Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 26-252: Belrapzo – Price for 4 ml Sully & Price per ml of Intravenous Solution (US$), June’2020
Figure 26-253: Bendamustine – Comparision of Treatment Cost of CLL uisng Branded & Generic Solution (US$), June’2020
Figure 26-254: Bendamustine – Comparision of Treatment Cost of CLL uisng Branded & Generic Solution (US$), June’2020
Figure 26-255: Talaporfin – Price for Various Supplies of Intravenous Powder (US$), June’2020
Figure 26-256: Tucidinostat – CFDA Approval Year by Indication
Figure 26-257: Epidaza – Price for Weekly & Monthly Treatment Supply (CNY/US$), June’2020
Figure 26-258: DC Beads – Price for 10ml Supply & Price per ml of 2mg/ml Solution (US$/GBP), June’2020
Figure 26-259: DC Beads – Cost of Single Procedure by Dosage Form (US$/GBP), June’2020
Figure 26-260: Temodar – FDA Approval Year by Dosage Form
Figure 26-261: Temodar – Patent Issue & Expiration Year
Figure 26-262: Temodex – Patent issue & Expiration Year
Figure 26-263: Temodar – Price for 6 Capsule Supply & Price per unit of various Dose Regimens (US$), May’2020
Figure 26-264: Temodar – Price for 14 Capsule Supply & Price per unit of various Dose Regimens (US$), May’2020
Figure 26-265: Temozolomide – Price for 6 Capsule Supply & Price per unit of various Dose Regimens (US$), May’2020
Figure 26-266: Temodar – Initial & Maintenance Dose for Anaplastic Astrocytoma (mg/m2)
Figure 26-267: Genexol-PM – Price for 100mg Vial (US$/INR), June’2020
Figure 26-268: Nanoxel M – Amount of Docetaxel by Vial
Figure 26-269: Methotrexate – Average Price of 10 ml Supply & Price per ml of 25mg/ml Intravenous Solution (US$), June’2020
Figure 26-270: Methotrexate – Average Price of Different Supplies of Oral Tablet (US$), June’2020
Figure 26-271: Methotrexate – Minimum & Maximum Duration of Initial Treatment Phase of ALL (Weeks), June’2020
Figure 26-272: Methotrexate – Single Treatment Cycle Cost in Initial & Maintenance Phase (US$), June’2020
Figure 26-273: Methotrexate – Minimum & Maximum Treatment Cost of Initial Phase of ALL (US$), June’2020
Figure 26-274: Methotrexate – Duration of Treatment & Rest Period for Choriocarcinoma Treatment (Days), June’2020
Figure 26-275: Methotrexate – Minimum & Maximum Treatment Cost of Single Day (US$), June’2020
Figure 26-276: Methotrexate – Minimum & Maximum Cost of Single Treatment Cycle (US$), June’2020
Figure 26-277: Trecondi – Price for 5 Vial Supply & Price per Vial of 1mg (GBP/US$), June’2020
Figure 26-278: Trecondi – Price for 5 Vial Supply & Price per Vial of 5mg (GBP/US$), June’2020
Figure 26-279: Treosulfan – Daily Adult Dose & Total Required Dose (g/m2), June’2020
Figure 26-280: Treosulfan – Minimum & Maximum Daily Pediatric Dose (g/m2), June’2020
Figure 26-281: Camtobell – Price for 2mg Intravenous Solution (KRW/US$), June’2020
Figure 26-282: Camtobell – Cost of Daily Treatment & Cost of One Treatment Cycle (KRW/US$), June’2020
Figure 26-283: Liposomal Paclitaxel – Approval Year by Brand Name
Figure 26-284: Amsacrine – Minimum & Maximum Recommended Dose (mg/m2)
Figure 26-285: Cyclophosphamide – FDA Approval Year by Companies
Figure 26-286: Cyclophosphamide – Average Price for 1gm, 2gm & 500mg Powder for Injection (US$), June’2020
Figure 26-287: Cyclophosphamide – Average Price for a Supply of 100 Capsules of 25mg & 50 mg Dose (US$), June’2020
Figure 26-288: Hikma’s Cyclophosphamide – Average Price for a Supply of 100 Capsules of 25mg Dose (US$), June’2020
Figure 26-289: Cyclophosphamide IV Solution – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June’2020
Figure 26-290: Cyclophosphamide Capsule – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June’2020
Figure 26-291: DoceAqualip – Price for 20mg & 80mg Supply of Intravenous Injection (INR/US$), June’2020
Figure 26-292: Doceaqualip – Recommended Dose by Indication (mg/m2 /3weeks), June’2020
Figure 26-293: Aredia – Price for 10 ml Supply & Price per ml of Various Dose Regimens (US$), June’2020
Figure 26-294: Aredia – Price for Price for 30mg & 90mg Powder for Injection (US$), June’2020
Figure 26-295: Aredia – Cost of Single Treatment Cycle by Dosage Forms (US$), June’2020
Figure 26-296: Nedaplatin – Minimum & Maximum Recommended Dose (mg/m2), June’2020
Figure 26-297: Cytarabin – Price for 25ml & 50ml Supply of 20mg/ml Intravenous Solution (US$), June’2020
Figure 26-298 Cytarabin – Price for 20ml Supply of 100mg/ml Intravenous Solution (US$), June’2020
Figure 26-299 Depocyt – Price for 5ml Supply & Price per ml of 10mg/ml Intravenous Solution (US$), June’2020
Figure 26-300: Cytarabin – Average Minimum & Maximum Cost of Daily Treatment of Acute Nonlymphocytic Leukemia (US$), June’2020
Figure 26-301: Cytarabin – Average Daily & Full Treatment Cost in Initial Phase of Manengial Leukemia (US$), June’2020